MetaVia Inc. (MTVA)Healthcare | Biotechnology | Cambridge, United States | NasdaqCM
1.99 USD
+0.21
(11.798%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 1.91 -0.08 (-0.077%) ⇩ (July 13, 2026, 7:57 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:10 a.m. EDT
The immediate outlook is neutral-to-slightly-bearish despite a recent spike driven by conference buzz, as the stock is trading significantly below its 50-day average and faces a massive reverse split that often introduces volatility. Fundamentally, this is a distressed biotech play with no earnings, negative free cash flow, and a catastrophic long-term price trajectory where the asset has lost nearly 100% of its value over the last eight years. The market has punished the company repeatedly, with seven out of eight years showing negative returns, indicating deep structural issues rather than a temporary setback. There is no dividend income to offset these risks, making this a speculative vehicle unsuitable for capital preservation. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.277516 |
| AutoTheta | 0.278336 |
| AutoETS | 0.278349 |
| AutoARIMA | 0.278349 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 0.11 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.284 |
| Excess Kurtosis | -0.79 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.138 |
| Market Cap | 10,277,096 |
| Beta | 0.97 |
| Previous Name | NeuroBo Pharmaceuticals, Inc. |
| Website | https://www.metaviatx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.7720871 |
| Address1 | 545 Concord Avenue |
| Address2 | Suite 210 |
| All Time High | 1,424,940.0 |
| All Time Low | 0.966 |
| Ask | 2.31 |
| Ask Size | 2 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 131,270 |
| Average Daily Volume3 Month | 3,825,337 |
| Average Volume | 3,825,337 |
| Average Volume10Days | 131,270 |
| Beta | 0.967 |
| Bid | 1.58 |
| Bid Size | 2 |
| Book Value | 1.757 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.99 |
| Current Ratio | 2.728 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 2.6098 |
| Day Low | 1.755 |
| Debt To Equity | 2.138 |
| Display Name | MetaVia |
| Dividend Date | 1,577,750,400 |
| Earnings Timestamp End | 1,755,520,200 |
| Earnings Timestamp Start | 1,755,001,800 |
| Ebitda | -13,827,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.236 |
| Enterprise Value | -3,261,903 |
| Eps Trailing Twelve Months | -4.21 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.8542 |
| Fifty Day Average Change | 0.1358 |
| Fifty Day Average Change Percent | 0.07323913 |
| Fifty Two Week Change Percent | -77.20871 |
| Fifty Two Week High | 19.03 |
| Fifty Two Week High Change | -17.04 |
| Fifty Two Week High Change Percent | -0.8954283 |
| Fifty Two Week Low | 0.966 |
| Fifty Two Week Low Change | 1.0239999 |
| Fifty Two Week Low Change Percent | 1.0600413 |
| Fifty Two Week Range | 0.966 - 19.03 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,470,403,800,000 |
| Float Shares | 3,381,475 |
| Free Cashflow | -10,425,375 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 8 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.36497003 |
| Held Percent Institutions | 0.13382 |
| Implied Shares Outstanding | 5,164,370 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,764,892,800 |
| Last Split Factor | 1:11 |
| Long Business Summary | MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. Its therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. The company has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts. |
| Long Name | MetaVia Inc. |
| Market | us_market |
| Market Cap | 10,277,096 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_630763379 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | -13,125,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 9,140,934 |
| Number Of Analyst Opinions | 3 |
| Open | 1.74 |
| Operating Cashflow | -15,144,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 857 702 9600 |
| Post Market Change | -0.077200055 |
| Post Market Change Percent | -3.8793998 |
| Post Market Price | 1.9128 |
| Post Market Time | 1,783,987,027 |
| Prev Name | NeuroBo Pharmaceuticals, Inc. |
| Previous Close | 1.78 |
| Price Hint | 4 |
| Price To Book | 1.1326125 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.645 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | 0.21 |
| Regular Market Change Percent | 11.7978 |
| Regular Market Day High | 2.6098 |
| Regular Market Day Low | 1.755 |
| Regular Market Day Range | 1.755 - 2.6098 |
| Regular Market Open | 1.74 |
| Regular Market Previous Close | 1.78 |
| Regular Market Price | 1.99 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 8,719,900 |
| Return On Assets | -0.65279 |
| Return On Equity | -1.95124 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 5,164,370 |
| Shares Percent Shares Out | 0.024 |
| Shares Short | 124,038 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 408,434 |
| Short Name | MetaVia Inc. |
| Short Percent Of Float | 0.0366 |
| Short Ratio | 0.1 |
| Source Interval | 15 |
| State | MA |
| Symbol | MTVA |
| Target High Price | 30.0 |
| Target Low Price | 8.0 |
| Target Mean Price | 19.33333 |
| Target Median Price | 20.0 |
| Total Cash | 13,733,000 |
| Total Cash Per Share | 2.659 |
| Total Debt | 194,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.21 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.82402 |
| Two Hundred Day Average Change | -2.83402 |
| Two Hundred Day Average Change Percent | -0.58748096 |
| Type Disp | Equity |
| Volume | 8,719,900 |
| Website | https://www.metaviatx.com |
| Zip | 2,138 |